Abstract
4-Aminobenzothieno[3,2-d]pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5,6-substituted 4-aminothieno[2,3-d]pyrimidines with low micromolar inhibition of LIMK1.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Cell Line, Tumor
-
Drug Design*
-
Drug Evaluation, Preclinical
-
Drug Screening Assays, Antitumor
-
High-Throughput Screening Assays
-
Humans
-
Hydrophobic and Hydrophilic Interactions
-
Inhibitory Concentration 50
-
Lim Kinases / antagonists & inhibitors*
-
Molecular Structure
-
Molecular Targeted Therapy*
-
Molecular Weight
-
Neoplasm Metastasis / drug therapy
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Stereoisomerism
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Lim Kinases